NYSE Shariah screener · October 2026

Is Stryker Corporation (SYK) Halal?

PASS

Stryker Corporation · NYSE: SYK · Healthcare

The short answer

Yes — Stryker Corporation (SYK) passes this Shariah stock screen. The medical technology company, led by Chair and CEO Kevin A. Lobo, sells orthopaedic implants (Knees, Hips, Trauma and Extremities, Spinal Implants), surgical instruments, endoscopy equipment and neurotechnology products — all healthcare activity, with no haram business segments disclosed in its FY2025 filings. The financial ratios pass comfortably: the Q2 2026 balance sheet shows interest-bearing debt of $14,942M (current maturities $750M + long-term debt $14,192M), which is 14.15% of its ~$105.6B market cap (October 2026), below the ~33% ceiling; and interest income is 0.48% of revenue (Zoya: $121M vs $25,116M FY2025 net sales), below the 5% ceiling — even the broader Other income line of $232M is just 0.92% of sales. Zoya lists SYK as Shariah-compliant (September 2026) but its page text renders contradictory wording (inconclusive); Musaffa and ShariaPortfolio show no SYK coverage. This is a factual screen, not a religious ruling — consult a qualified scholar for personal rulings.

Gate 1 — Business activity: PASS

Stryker Corporation (NYSE: SYK) is a medical technology company led by Chair and CEO Kevin A. Lobo. It reports two segments: MedSurg and Neurotechnology (Instruments, Endoscopy, Medical, Vascular — its neurovascular business was renamed Vascular in Q1 2025 after the Inari acquisition — and Neuro Cranial) and Orthopaedics (Knees, Hips, Trauma and Extremities, Spinal Implants and Other) — orthopaedic implants, surgical equipment and neurotechnology products. FY2025 net sales of $25,116M (United States $19,006M; International $6,110M) all come from medical-device activity. Business-screen implication (factual): all activity is healthcare/medical devices; the filings disclose no alcohol, gambling, conventional finance, pork, weapons or tobacco revenue — no haram segments. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

Per Stryker's 2026 Second Quarter Form 10-Q (SEC CIK 0000310764), the condensed consolidated balance sheet at June 30, 2026 lists current maturities of debt of $750M and long-term debt, excluding current maturities, of $14,192M — total interest-bearing debt of $14,942M. Against a market cap of about $105.6B (marketcap.company, October 1, 2026), debt ÷ market cap is 14.15% — below the ~33% ceiling. Cash and cash equivalents of $3,391M plus marketable securities of $85M ($3,476M combined) are about 3.29% of market cap, also below 33%. The debt gate passes. Facts only.

Gate 3 — Non-compliant income: PASS

Stryker's 2025 Form 10-K (year ended December 31, 2025; SEC CIK 0000310764) reports net sales of $25,116M. Stryker reports interest income inside its 'Other income' line of $232M — about 0.92% of net sales, below the 5% non-compliant income ceiling, so even the broadest verifiable interest-income container passes. Zoya's SYK page independently cites FY2025 interest income of $121M — about 0.48% of $25,116M revenue, also below 5%. FY2025 interest expense was $607M. The income gate passes. Facts only.

Key figures used

Business: Stryker Corporation (NYSE: SYK), medical technology led by Chair and CEO Kevin A. Lobo — MedSurg and Neurotechnology (Instruments, Endoscopy, Medical, Vascular, Neuro Cranial); Orthopaedics (Knees, Hips, Trauma and Extremities, Spinal Implants, Other); no haram segments disclosed
FY2025 net sales $25,116M (United States $19,006M; International $6,110M) — 2025 Form 10-K (SEC CIK 0000310764)
Debt: $14,942M total interest-bearing debt at Jun 30, 2026 (current maturities $750M + long-term debt $14,192M, Q2 2026 10-Q); debt ÷ market cap = 14.15% of ~$105.6B, under the ~33% ceiling
Market cap ~$105.6B (marketcap.company, October 1, 2026, NYSE: SYK)
Cash & securities: $3,476M at Jun 30, 2026 ($3,391M cash + $85M marketable securities) ≈ 3.29% of market cap
Interest income: Zoya cites $121M (0.48% of $25,116M revenue); 10-K 'Other income' $232M = 0.92% of net sales — both under the 5% ceiling; interest expense $607M
Zoya: SYK page exists (interest income $121M, 0.48%) but rating text contradictory — inconclusive; Musaffa: no SYK page found; ShariaPortfolio: no SYK entry found

Frequently asked questions

What does Stryker do?

Stryker Corporation (NYSE: SYK) is a medical technology company led by Chair and CEO Kevin A. Lobo. It reports two segments: MedSurg and Neurotechnology (Instruments, Endoscopy, Medical, Vascular, Neuro Cranial) and Orthopaedics (Knees, Hips, Trauma and Extremities, Spinal Implants and Other) — orthopaedic implants, surgical equipment and neurotechnology products. FY2025 net sales were $25,116M (United States $19,006M; International $6,110M), all medical-device activity with no haram segments disclosed in the 10-K.

Why does SYK pass this Shariah stock screen?

SYK passes this Shariah stock screen at all three gates. Gate 1 (business activities): orthopaedic implants, surgical instruments, endoscopy, medical and vascular/neurotechnology products are healthcare activity — the FY2025 filings disclose no alcohol, gambling, conventional finance, pork, weapons or tobacco revenue. Gate 2 (debt): the Q2 2026 condensed consolidated balance sheet shows interest-bearing debt of $14,942M (current maturities $750M + long-term debt $14,192M), which is 14.15% of the ~$105.6B market cap, below the ~33% ceiling. Gate 3 (interest income): Zoya reports FY2025 interest income of $121M, 0.48% of $25,116M net sales, under the 5% ceiling — and the 10-K’s broader Other income line of $232M is just 0.92% of sales. This is a factual screen, not a religious ruling — consult a qualified scholar for personal rulings.

What is SYK's interest-bearing debt ratio?

Per Stryker’s 2026 Second Quarter Form 10-Q (SEC CIK 0000310764), the condensed consolidated balance sheet at June 30, 2026 lists current maturities of debt of $750M and long-term debt, excluding current maturities, of $14,192M — total interest-bearing debt of $14,942M. Against a market cap of about $105.6B (marketcap.company, October 1, 2026), debt ÷ market cap is 14.15% — below the ~33% ceiling. Cash and cash equivalents of $3,391M plus marketable securities of $85M ($3,476M combined) are about 3.29% of market cap, also below 33%. The debt gate passes.

What is SYK's non-compliant income ratio?

Stryker’s 2025 Form 10-K (year ended December 31, 2025; SEC CIK 0000310764) reports net sales of $25,116M. Zoya’s SYK page cites interest income of $121M from the FY2025 annual report — about 0.48% of $25,116M revenue, below the 5% non-compliant income ceiling. Stryker’s own income statement reports interest income inside the ‘Other income’ line of $232M, which is about 0.92% of net sales — so even the broadest verifiable interest-income container is under 5%. FY2025 interest expense was $607M. The income gate passes.

Do Zoya, Musaffa, or ShariaPortfolio cover SYK?

Zoya covers SYK (zoya.finance/stocks/syk; updated September 2026): its page lists Stryker as Shariah-compliant and cites the same $121M FY2025 interest income (0.48% of $25,116M revenue), but its public page renders contradictory auto-generated template text (simultaneously calling SYK Shariah-compliant/halal and not), so no clean Zoya rating is retrievable — reported as inconclusive. Musaffa: no SYK page was found via public search — no coverage found. ShariaPortfolio: no SYK entry found via public search — no coverage found. All honestly reported as found, not invented. This page applies the screen directly from Stryker’s own filings.

Sources

Screened 2026-10-01 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).